Why Express Scripts Is Poised to Outperform
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmacy benefit manager Express Scripts has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Express Scripts and see what CAPS investors are saying about the stock right now.
Express Scriptsfacts
Headquarters (founded) | St. Louis (1986) |
Market Cap | $48.0 billion |
Industry | Healthcare services |
Trailing-12-Month Revenue | $93.9 billion |
Management | Chairman/CEO George Paz |
Return on Equity (average, past 3 years) | 28.7% |
Cash/Debt | $2.8 billion / $15.9 billion |
Competitors | Aetna |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 94% of the 840 members who have rated Express Scripts believe the stock will outperform the S&P 500 going forward.
Just yesterday, one of those Fools, adamlevy, succinctly summed up Express Scripts bull case for our community:
With an aging population that's becoming more reliant on prescription drugs the entire health care sector is poised to gain.
Additionally, Express Scripts stands to gain from the impending patent-cliffs of several blockbuster drugs in 2013 and 2014.
The company also has its foot in the booming specialty drug treatment market, and the purchase of Medco last year increases its position in cancer treatment, which is one of the fastest growing segments.
Finally, Obamacare will increase the number of insured citizens. While most will be through medicare, one of Express Scripts largest clients, WellPoint, is the biggest medicare-based insurer. This means a flood of new customers for Express Scripts.
If you want market-topping returns, you need to put together the best portfolio you can. Of course, despite its perfect five-star rating, Express Scripts may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Express Scripts Is Poised to Outperform originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Express Scripts and WellPoint. The Motley Fool owns shares of Express Scripts and WellPoint. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
